Affinity Asset Advisors’s Cullinan Oncology CGEM Stock Holding History

Affinity Asset Advisors’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.9M	Buy	875,760 +94,500	+12%	+$1.4M	0.72%	40
2026 Q1	$11.1M	Sell	781,260 -1,150,846	-60%	-$14.8M	0.57%	46
2025 Q4	$20M	Buy	1,932,106 +1,668,289	+632%	+$15M	1.14%	27
2025 Q3	$1.56M	Hold	263,817	–	–	0.14%	79
2025 Q2	$1.99M	Hold	263,817	–	–	0.27%	56
2025 Q1	$2M	Hold	263,817	–	–	0.19%	68
2024 Q4	$3.21M	Hold	263,817	–	–	0.43%	49
2024 Q3	$4.42M	Hold	263,817	–	–	0.6%	45
2024 Q2	$4.6M	Buy	263,817 +5,229	+2%	+$111K	0.53%	44
2024 Q1	$4.41M	Sell	258,588 -41,412	-14%	-$640K	0.55%	55
2023 Q4	$3.06M	Buy	+300,000	New	+$2.66M	0.56%	47
2021 Q3	–	Sell	-45,000	Closed	-$1.16M	–	78
2021 Q2	$1.16M	Buy	+45,000	New	+$1.38M	0.41%	49

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Affinity Asset Advisors's CGEM Position: Q2 2026 in Review

Affinity Asset Advisors increased its Cullinan Oncology (CGEM) stake by 12% in Q2 2026, buying an estimated $1.4M and bringing the position to 875,760 shares worth $15.9M. The position accounts for 0.72% of the portfolio, ranked #40.

Affinity Asset Advisors first reported a position in CGEM in Q2 2021 and has held it in 12 quarters since. The position peaked at $20M in Q4 2025. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

Affinity Asset Advisors held 875,760 shares of Cullinan Oncology worth $15.9M as of Q2 2026.
Affinity Asset Advisors bought 94,500 Cullinan Oncology shares in Q2 2026, an estimated $1.4M.
Cullinan Oncology made up 0.72% of Affinity Asset Advisors's portfolio in Q2 2026, its #40 holding.
Affinity Asset Advisors first reported a position in Cullinan Oncology in Q2 2021 and has held it in 12 quarters since.
Affinity Asset Advisors's Cullinan Oncology position peaked at $20M in Q4 2025.
184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.